Assessing risk across the spectrum of patients with the metabolic syndrome

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


The metabolic syndrome represents a constellation of interrelated risk factors that identify individuals at increased risk for the development of type 2 diabetes mellitus and cardiovascular events. Currently, the major cardiovascular risk factors and validated risk-assessment tools do not adequately account for the increased cardiovascular risk that accompanies the metabolic syndrome. In prospective population studies, cardiovascular risk assessment in individuals with the metabolic syndrome is improved by measures of low-density lipoprotein (LDL) particle number, C-reactive protein, and plasminogen activator inhibitor-1 levels. Although adiponectin and soluble tumor necrosis factor receptor-2 may be more integrally involved in insulin resistance, the studies with these biomarkers are less extensive. Risk assessment models for patients with the metabolic syndrome should consider inclusion of LDL particle number, inflammatory markers, and levels of plasminogen activator inhibitor-1.

Original languageEnglish
Pages (from-to)8-10
Number of pages3
JournalAmerican Journal of Cardiology
Issue number4 SUPPL.
StatePublished - 22 Aug 2005
Externally publishedYes


Dive into the research topics of 'Assessing risk across the spectrum of patients with the metabolic syndrome'. Together they form a unique fingerprint.

Cite this